Background: Early identification of Alzheimer's disease (AD) is essential for optimal treatment and management. Deep learning (DL) technologies, including convolutional neural networks (CNNs) and vision transformers (ViTs) can provide promising outcomes in AD diagnosis. However, these technologies lack model interpretability and demand substantial computational resources, causing challenges in the resource-constrained environment. Hybrid ViTs can outperform individual ViTs by visualizing key features with limited computational power. This synergy enhances feature extraction and promotes model interpretability.
Objectives: Thus, the authors present an innovative model for classifying AD using MRI images with limited computational resources.
Methods: The authors improved the AD feature-extraction process by modifying the existing ViTs. A CatBoost-based classifier was used to classify the extracted features into multiple classes.
Results: The proposed model was generalized using the OASIS dataset. The model obtained an exceptional classification accuracy of 98.8% with a minimal loss of 0.12.
Conclusions: The findings highlight the potential of the proposed AD classification model in providing an interpretable and resource-efficient solution for healthcare centers. To improve model robustness and applicability, subsequent research can include genetic and clinical data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11545033 | PMC |
http://dx.doi.org/10.3390/diagnostics14212363 | DOI Listing |
Alzheimers Dement
December 2024
7T Magnetic Resonance Imaging Translational Medical Center, Department of Radiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Introduction: The choroid plexus (CP) may play a crucial role in brain degeneration. We aim to assess whether CP cysts (CPCs), defined using ultra-high field magnetic resonance imaging (MRI), relate to aging and neurodegeneration.
Methods: We used multi-sequence 7T MRI to observe CPCs, characterizing their presence and characteristics in healthy younger controls, healthy older controls (OCs), patients with Alzheimer's disease (AD), patients with Parkinson's disease (PD), and patients with uremic encephalopathy.
Alzheimers Dement
December 2024
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Introduction: Type 2 diabetes increases the risk of Alzheimer's disease (AD) dementia. Insulin signaling dysfunction exacerbates tau protein phosphorylation, a hallmark of AD pathology. However, the comprehensive impact of diabetes on patterns of AD-related phosphoprotein in the human brain remains underexplored.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
Introduction: Alzheimer's disease (AD) is now diagnosed biologically. Since subjective cognitive decline (SCD) may indicate preclinical AD, assessing AD-biomarkers is crucial. We investigated cognitive and neurodegenerative trajectories in SCD over 24 months based on biomarker positivity, and evaluated the predictive value of plasma biomarkers.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Alzheimers Dement
December 2024
Center on Aging Psychology, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China.
Introduction: Subjective cognitive decline (SCD) is linked to memory complaints and disruptions in certain brain regions identified by molecular imaging and resting-state functional magnetic resonance imaging studies. However, it remains unclear how these regions interact to contribute to both subjective and potential objective memory issues in SCD.
Methods: To address this gap, task-based imaging studies are essential.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!